Chlorhexidine Lavage for Recurrent Urinary Tract Infection

What this trial studies

A two-arm randomized control trial evaluating rates of urinary tract infection in post-menopausal women on vaginal estrogen with recurrent urinary tract infections.

Conditions in scope

• Urinary Tract Infections
• Recurrent Urinary Tract Infection

Interventions

• Chlorhexidine (Drug) — Participants will use a 2% chlorhexidine perineal lavage following defecation
• Sterile Water (Drug) — Participants will use a sterile water perineal lavage following defecation

Who can join

Women only · Ages 55 Years to 89 Years

Inclusion criteria

• Post-menopausal female between age 55 and 89
• No post-menopausal bleeding
• Diagnosis of recurrent urinary tract infection (UTI) in the electronic health record or as two culture proven UTIs in 6 months or three culture proven UTIs in 12 months
• At least one UTI in the 6 months prior to entering the study
• Asymptomatic for UTI symptoms at the time of enrollment.
• On vaginal estrogen therapy for at least 6 weeks prior to enrollment
• Ready access to email and internet

Exclusion criteria

• Recent prophylactic antibiotic use (washout period of 4 weeks)
• Neurogenic bladder
• Diagnosis of urinary retention
• Uncorrected Stage III-IV prolapse
• Indwelling catheter or need for intermittent self-catheterization
• History of complicated UTIs
• History of interstitial cystitis or bladder pain syndrome
• History of fecal incontinence/accidental bowel leakage

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Active, not recruiting
• Study type: Interventional
• Phase: PHASE4
• Start date: 2024-12-23
• Primary completion: 2026-04
• Last update posted: 2026-01-15
• First posted: 2024-09-19

Sponsor & contact

Lead sponsor: Oregon Health and Science University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Rate of Urinary Tract Infection (UTI) (90 days following treatment initiation)
  The proportion of participants in each arm who experience a urinary tract infection (UTI) within 90 days will be compared

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.